{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:52:21Z","timestamp":1788274341247,"version":"build-2803163510"},"reference-count":178,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministerio de Ciencia e Innovaci\u00f3n-FEDER","award":["PID2019-105610RB-I00"],"award-info":[{"award-number":["PID2019-105610RB-I00"]}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n-FEDER","award":["RED2018-102801-T"],"award-info":[{"award-number":["RED2018-102801-T"]}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n-FEDER","award":["CSI264P20"],"award-info":[{"award-number":["CSI264P20"]}]},{"name":"Ministerio de Ciencia e Innovaci\u00f3n-FEDER","award":["CLC-2017-01"],"award-info":[{"award-number":["CLC-2017-01"]}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n de la Junta de Castilla y Le\u00f3n-FEDER","doi-asserted-by":"publisher","award":["PID2019-105610RB-I00"],"award-info":[{"award-number":["PID2019-105610RB-I00"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n de la Junta de Castilla y Le\u00f3n-FEDER","doi-asserted-by":"publisher","award":["RED2018-102801-T"],"award-info":[{"award-number":["RED2018-102801-T"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n de la Junta de Castilla y Le\u00f3n-FEDER","doi-asserted-by":"publisher","award":["CSI264P20"],"award-info":[{"award-number":["CSI264P20"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n de la Junta de Castilla y Le\u00f3n-FEDER","doi-asserted-by":"publisher","award":["CLC-2017-01"],"award-info":[{"award-number":["CLC-2017-01"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Synthetic lethality strategies are likely to be integrated in effective and specific cancer treatments. These strategies combine different specific targets, either in similar or cooperating pathways. Chromatin remodeling underlies, directly or indirectly, all processes of tumor biology. In this context, the combined targeting of proteins associated with different aspects of chromatin remodeling can be exploited to find new alternative targets or to improve treatment for specific individual tumors or patients. There are two major types of proteins, epigenetic modifiers of histones and nuclear or chromatin kinases, all of which are druggable targets. Among epigenetic enzymes, there are four major families: histones acetylases, deacetylases, methylases and demethylases. All these enzymes are druggable. Among chromatin kinases are those associated with DNA damage responses, such as Aurora A\/B, Haspin, ATM, ATR, DNA-PK and VRK1\u2014a nucleosomal histone kinase. All these proteins converge on the dynamic regulation chromatin organization, and its functions condition the tumor cell viability. Therefore, the combined targeting of these epigenetic enzymes, in synthetic lethality strategies, can sensitize tumor cells to toxic DNA-damage-based treatments, reducing their toxicity and the selective pressure for tumor resistance and increasing their immunogenicity, which will lead to an improvement in disease-free survival and quality of life.<\/jats:p>","DOI":"10.3390\/cancers14164050","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T21:30:34Z","timestamp":1661203834000},"page":"4050","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8997-3025","authenticated-orcid":false,"given":"Pedro A.","family":"Lazo","sequence":"first","affiliation":[{"name":"Molecular Mechanisms of Cancer Program, Instituto de Biolog\u00eda Molecular y Celular del C\u00e1ncer, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Universidad de Salamanca, 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca-IBSAL, Hospital Universitario de Salamanca, 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"ref_1","unstructured":"Consortium ITP-CAoWG (2020). Pan-cancer analysis of whole genomes. Nature, 578, 82\u201393."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mularoni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ccell.2019.12.004","article-title":"Cancer Genome Evolutionary Trajectories in Metastasis","volume":"37","author":"Birkbak","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1535-7163.MCT-21-0500","article-title":"Synthetic Lethality in Ovarian Cancer","volume":"20","author":"Chandrasekaran","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10555-021-09983-1","article-title":"Targeting DNA damage repair pathways in pancreas cancer","volume":"40","author":"Crowley","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/CCO.0000000000000654","article-title":"Targeting defective DNA repair in prostate cancer","volume":"32","author":"Carmichael","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1158\/0008-5472.CAN-16-2773","article-title":"Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1158\/2159-8290.CD-17-0343","article-title":"Tumor Evolution as a Therapeutic Target","volume":"7","author":"Swanton","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA Damage and Repair Biomarkers of Immunotherapy Response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ng.3581","article-title":"Landscape of tumor-infiltrating T cell repertoire of human cancers","volume":"48","author":"Li","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.canlet.2020.12.032","article-title":"The human VRK1 chromatin kinase in cancer biology","volume":"503","author":"Lazo","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jmb.2014.05.025","article-title":"Reshaping chromatin after DNA damage: The choreography of histone proteins","volume":"427","author":"Polo","year":"2015","journal-title":"J. Mol. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41467-021-22024-3","article-title":"Epigenetic mechanisms in breast cancer therapy and resistance","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1158\/0008-5472.CAN-08-3907","article-title":"Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome","volume":"69","author":"Elsheikh","year":"2009","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1111\/bph.12844","article-title":"Targeting the histone orthography of cancer: Drugs for writers, erasers and readers","volume":"172","author":"Esteller","year":"2015","journal-title":"Br. J. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-981-15-8104-5_3","article-title":"Histone H3K27M Mutation in Brain Tumors","volume":"1283","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11316","DOI":"10.1038\/ncomms11316","article-title":"Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2","volume":"7","author":"Justin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.aac7272","article-title":"Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape","volume":"352","author":"Lu","year":"2016","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41594-019-0298-7","article-title":"Histone lysine methyltransferases in biology and disease","volume":"26","author":"Husmann","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejmech.2019.01.069","article-title":"Histone methyl transferases: A class of epigenetic opportunities to counter uncontrolled cell proliferation","volume":"166","author":"Singh","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13148-018-0601-1","article-title":"The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness","volume":"11","author":"Kari","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1124\/jpet.114.214577","article-title":"DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells","volume":"350","author":"Klaus","year":"2014","journal-title":"J. Pharm. Exp."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nm.3832","article-title":"DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia","volume":"21","author":"Chen","year":"2015","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-20-2147","article-title":"EZH2-Targeted Therapies in Cancer: Hype or a Reality","volume":"80","author":"Eich","year":"2020","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"715126","DOI":"10.3389\/fcell.2021.715126","article-title":"Lysine Methyltransferase Inhibitors Impair H4K20me2 and 53BP1 Foci in Response to DNA Damage in Sarcomas, a Synthetic Lethality Strategy","volume":"9","author":"Lazo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1111\/cas.15122","article-title":"The EZH2 inhibitor tazemetostat upregulates the expression of CCL17\/TARC in B-cell lymphoma and enhances T-cell recruitment","volume":"112","author":"Yuan","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(20)30451-4","article-title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: An international, open-label, phase 2 basket study","volume":"21","author":"Gounder","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/15384047.2021.1902913","article-title":"Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitro","volume":"22","author":"Narendran","year":"2021","journal-title":"Cancer Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccell.2019.12.015","article-title":"EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition","volume":"37","author":"Karakashev","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/nature09658","article-title":"MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites","volume":"470","author":"Pei","year":"2011","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1007\/s00018-019-03144-y","article-title":"Understanding histone H3 lysine 36 methylation and its deregulation in disease","volume":"76","author":"Li","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13750","DOI":"10.1074\/jbc.RA118.004274","article-title":"High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2","volume":"293","author":"Coussens","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Popovic, R., Martinez-Garcia, E., Giannopoulou, E.G., Zhang, Q., Zhang, Q., Ezponda, T., Shah, M.Y., Zheng, Y., Will, C.M., and Small, E.C. (2014). Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet., 10.","DOI":"10.1371\/journal.pgen.1004566"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.molcel.2011.08.042","article-title":"NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming","volume":"44","author":"Kuo","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41467-021-21386-y","article-title":"Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/19491034.2018.1444327","article-title":"H4K20me2: Orchestrating the recruitment of DNA repair factors in nucleotide excision repair","volume":"9","author":"Chitale","year":"2018","journal-title":"Nucleus"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.201704028","article-title":"DICER- and MMSET-catalyzed H4K20me2 recruits the nucleotide excision repair factor XPA to DNA damage sites","volume":"217","author":"Chitale","year":"2018","journal-title":"J. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e02482","DOI":"10.7554\/eLife.02482","article-title":"SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint","volume":"3","author":"Carvalho","year":"2014","journal-title":"eLife"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11951","DOI":"10.1074\/jbc.M117.788224","article-title":"Cross-talk between the H3K36me3 and H4K16ac histone epigenetic marks in DNA double-strand break repair","volume":"292","author":"Li","year":"2017","journal-title":"J. Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1128\/MCB.01382-07","article-title":"DNA damage-induced acetylation of lysine 3016 of ATM activates ATM kinase activity","volume":"27","author":"Sun","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Garcia-Gonzalez, R., Morejon-Garcia, P., Campillo-Marcos, I., Salzano, M., and Lazo, P.A. (2020). VRK1 Phosphorylates Tip60\/KAT5 and Is Required for H4K16 Acetylation in Response to DNA Damage. Cancers, 12.","DOI":"10.3390\/cancers12102986"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1021\/acsmedchemlett.1c00272","article-title":"Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies","volume":"12","author":"Lampe","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrm4043","article-title":"DNA methylation pathways and their crosstalk with histone methylation","volume":"16","author":"Du","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1101\/gad.1837309","article-title":"SetDB1 contributes to repression of genes encoding developmental regulators and maintenance of ES cell state","volume":"23","author":"Bilodeau","year":"2009","journal-title":"Genes Dev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.molcel.2015.10.025","article-title":"H3K4\/H3K9me3 Bivalent Chromatin Domains Targeted by Lineage-Specific DNA Methylation Pauses Adipocyte Differentiation","volume":"60","author":"Matsumura","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1038\/onc.2013.239","article-title":"Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis","volume":"33","author":"Sayols","year":"2014","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","article-title":"Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity","volume":"595","author":"Griffin","year":"2021","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Flesher, J.L., and Fisher, D.E. (2021). G9a: An Emerging Epigenetic Target for Melanoma Therapy. Epigenomes, 5.","DOI":"10.3390\/epigenomes5040023"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/1535-7163.MCT-21-0743","article-title":"Dual G9A\/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma","volume":"21","author":"Spiliopoulou","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41389-021-00370-7","article-title":"Emerging role of G9a in cancer stemness and promises as a therapeutic target","volume":"10","author":"Haebe","year":"2021","journal-title":"Oncogenesis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1078-0432.CCR-18-0098","article-title":"The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies","volume":"25","author":"Stubbs","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/09553002.2021.1872813","article-title":"Chaetocin induced chromatin condensation: Effect on DNA repair signaling and survival","volume":"97","author":"Sak","year":"2021","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e2098","DOI":"10.1038\/cddis.2016.15","article-title":"The anticancer effect of chaetocin is enhanced by inhibition of autophagy","volume":"7","author":"Jung","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ccell.2018.02.002","article-title":"ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia","volume":"33","author":"Maes","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.18632\/aging.102887","article-title":"The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: A potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes","volume":"12","author":"Gumuzio","year":"2020","journal-title":"Aging"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1158\/0008-5472.CAN-16-3502","article-title":"LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B","volume":"77","author":"Takagi","year":"2017","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2217\/epi-2016-0009","article-title":"LSD1: Biologic roles and therapeutic targeting","volume":"8","author":"Somervaille","year":"2016","journal-title":"Epigenomics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","article-title":"A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC","volume":"28","author":"Mohammad","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/med.21334","article-title":"Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date","volume":"35","author":"Mould","year":"2015","journal-title":"Med. Res. Rev."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eabl7989","DOI":"10.1126\/scisignal.abl7989","article-title":"Targeting the lysine-specific demethylase 1 rewires kinase networks and primes leukemia cells for kinase inhibitor treatment","volume":"15","author":"Pedicona","year":"2022","journal-title":"Sci. Signal."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","article-title":"Re-programing Chromatin with a Bifunctional LSD1\/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG","volume":"36","author":"Anastas","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"eaau2922","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ccell.2018.02.014","article-title":"ORY-1001: Overcoming the Differentiation Block in AML","volume":"33","author":"Bose","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.celrep.2017.09.078","article-title":"UTX\/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition","volume":"21","author":"Ezponda","year":"2017","journal-title":"Cell Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1038\/onc.2014.453","article-title":"KATs in cancer: Functions and therapies","volume":"34","author":"Farria","year":"2015","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neo.2021.12.002","article-title":"Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer","volume":"24","author":"Wilson","year":"2022","journal-title":"Neoplasia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.clml.2021.06.020","article-title":"Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma","volume":"21","author":"Berdeja","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1158\/1078-0432.CCR-18-0260","article-title":"Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/febs.15750","article-title":"Clinical advances in targeting epigenetics for cancer therapy","volume":"289","author":"Feng","year":"2022","journal-title":"FEBS J."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1038\/s41388-021-01834-1","article-title":"Targeting the p300\/NONO axis sensitizes melanoma cells to BRAF inhibitors","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"ref_83","first-page":"10017","article-title":"The multifaceted influence of histone deacetylases on DNA damage signalling and DNA repair","volume":"44","author":"Roos","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC Inhibitors in Cancer Development and Therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1369\/0022155413506582","article-title":"Histone deacetylases: A saga of perturbed acetylation homeostasis in cancer","volume":"62","author":"Parbin","year":"2014","journal-title":"J. Histochem. Cytochem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4161\/15592294.2014.983367","article-title":"Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma","volume":"9","author":"Mithraprabhu","year":"2014","journal-title":"Epigenetics"},{"key":"ref_87","first-page":"1181","article-title":"Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid","volume":"30","author":"Rikiishi","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-016-2979-9","article-title":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription","volume":"77","author":"Ye","year":"2016","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.semcancer.2009.02.005","article-title":"Epigenetic mechanisms in glioblastoma multiforme","volume":"19","author":"Nagarajan","year":"2009","journal-title":"Semin. Cancer Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13148-018-0598-5","article-title":"Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells","volume":"11","author":"Was","year":"2019","journal-title":"Clin. Epigenet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"107721","DOI":"10.1016\/j.pharmthera.2020.107721","article-title":"Targeting post-translational histone modifying enzymes in glioblastoma","volume":"220","author":"Kunadis","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1093\/carcin\/bgt033","article-title":"Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells","volume":"34","author":"Vasilatos","year":"2013","journal-title":"Carcinogenesis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13072-015-0021-9","article-title":"Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response","volume":"8","author":"Halsall","year":"2015","journal-title":"Epigenetics Chromatin"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/jnci\/djm044","article-title":"Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide","volume":"99","author":"Keshelava","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1158\/1078-0432.CCR-04-2088","article-title":"Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity","volume":"11","author":"Munshi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Syn.nthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA Repair in Cancer: Beyond PARP Inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1158\/1078-0432.CCR-20-2357","article-title":"Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma","volume":"27","author":"Xiao","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2217\/epi.15.16","article-title":"Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy","volume":"7","author":"Park","year":"2015","journal-title":"Epigenomics"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","article-title":"Targeting the epigenetic regulation of antitumour immunity","volume":"19","author":"Hogg","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0092-8674(04)00126-6","article-title":"Mammalian SIRT1 represses forkhead transcription factors","volume":"116","author":"Motta","year":"2004","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/nar\/gkp1039","article-title":"SIRT1 deacetylates APE1 and regulates cellular base excision repair","volume":"38","author":"Yamamori","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/0008-5472.CAN-08-3365","article-title":"The critical role of the class III histone deacetylase SIRT1 in cancer","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41419-019-1592-3","article-title":"SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer","volume":"10","author":"Yousafzai","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbrc.2010.08.118","article-title":"Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells","volume":"401","author":"Kalle","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1074\/jbc.M113.487736","article-title":"A novel sirtuin 2 (SIRT2) inhibitor with p53-dependent pro-apoptotic activity in non-small cell lung cancer","volume":"289","author":"Hoffmann","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccell.2016.02.007","article-title":"A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity","volume":"29","author":"Jing","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrc1560","article-title":"The role of apoptosis in cancer development and treatment response","volume":"5","author":"Brown","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1042\/BST20160081","article-title":"Targeting cancer using KAT inhibitors to mimic lethal knockouts","volume":"44","author":"Brown","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/nature06055","article-title":"Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response","volume":"448","author":"Gorrini","year":"2007","journal-title":"Nature"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"13182","DOI":"10.1073\/pnas.0504211102","article-title":"A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM","volume":"102","author":"Sun","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/dvdy.22110","article-title":"Homozygous disruption of the Tip60 gene causes early embryonic lethality","volume":"238","author":"Hu","year":"2009","journal-title":"Dev. Dyn."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"18218","DOI":"10.1074\/jbc.M802332200","article-title":"Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance","volume":"283","author":"Miyamoto","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1093\/carcin\/bgr292","article-title":"Activation of a Tip60\/E2F1\/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin","volume":"33","author":"Nissou","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/ncb1343","article-title":"Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks","volume":"8","author":"Murr","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"10078","DOI":"10.1038\/s41598-021-89530-8","article-title":"C646 inhibits G2\/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer","volume":"11","author":"Ono","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e12291","DOI":"10.15252\/emmm.202012291","article-title":"SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells","volume":"12","author":"Tao","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3892\/ijo.2017.4176","article-title":"Histone acetyltransferase p300\/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines","volume":"51","author":"Wang","year":"2017","journal-title":"Int. J. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ccell.2020.11.006","article-title":"DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity","volume":"39","author":"Lu","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41586-020-2493-4","article-title":"Expanded encyclopaedias of DNA elements in the human and mouse genomes","volume":"583","author":"Abascal","year":"2020","journal-title":"Nature"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.18632\/oncotarget.1678","article-title":"Vaccinia-related kinase 1 (VRK1) confers resistance to DNA-damaging agents in human breast cancer by affecting DNA damage response","volume":"5","author":"Salzano","year":"2014","journal-title":"Oncotarget"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"683038","DOI":"10.3389\/fcell.2021.683038","article-title":"VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells","volume":"9","author":"Lazo","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13046-019-1204-1","article-title":"Olaparib and ionizing radiation trigger a cooperative DNA-damage repair response that is impaired by depletion of the VRK1 chromatin kinase","volume":"38","author":"Lazo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/0008-5472.CAN-19-2330","article-title":"Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity","volume":"80","author":"Melms","year":"2020","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/onc.2011.335","article-title":"Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin","volume":"31","author":"Huertas","year":"2012","journal-title":"Oncogene"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1158\/0008-5472.CAN-05-3353","article-title":"The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function","volume":"66","author":"Gizatullin","year":"2006","journal-title":"Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/1535-7163.MCT-09-0041","article-title":"GSK1070916, a potent Aurora B\/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models","volume":"8","author":"Hardwicke","year":"2009","journal-title":"Mol. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1535-7163.MCT-17-0223","article-title":"Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer","volume":"16","author":"Montero","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","article-title":"Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses","volume":"15","author":"Owonikoko","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e183773","DOI":"10.1001\/jamaoncol.2018.3773","article-title":"Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial","volume":"5","author":"Falchook","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-11-2413","article-title":"Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma","volume":"18","author":"Mahadevan","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11523-019-00662-4","article-title":"Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing Lymphoma","volume":"14","author":"Park","year":"2019","journal-title":"Target. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1535-7163.MCT-15-0897","article-title":"Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics","volume":"15","author":"Gutteridge","year":"2016","journal-title":"Mol. Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1038\/s41467-020-17697-1","article-title":"PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance","volume":"11","author":"Montaudon","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3109\/09553002.2015.1001531","article-title":"The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect","volume":"91","author":"Zhang","year":"2015","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"102971","DOI":"10.1016\/j.ebiom.2020.102971","article-title":"Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma","volume":"59","author":"George","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2021.11.011","article-title":"A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer","volume":"163","author":"Plummer","year":"2022","journal-title":"Lung Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nsmb.2076","article-title":"A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations","volume":"18","author":"Toledo","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neo.2022.01.004","article-title":"Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer","volume":"25","author":"Smithson","year":"2022","journal-title":"Neoplasia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-022-04403-y","article-title":"Signatures of TOP1 transcription-associated mutagenesis in cancer and germline","volume":"602","author":"Reijns","year":"2022","journal-title":"Nature"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.drudis.2017.10.005","article-title":"Haspin: A promising target for the design of inhibitors as potent anticancer drugs","volume":"23","author":"Amoussou","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Nishida-Fukuda, H., Tokuhiro, K., Ando, Y., Matsushita, H., Wada, M., and Tanaka, H. (2021). Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0249912"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e21923","DOI":"10.1096\/fj.202100099R","article-title":"Loss of haspin suppresses cancer cell proliferation by interfering with cell cycle progression at multiple stages","volume":"35","author":"Wang","year":"2021","journal-title":"FASEB J."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1038\/s41388-020-1296-2","article-title":"Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition","volume":"39","author":"Huang","year":"2020","journal-title":"Oncogene"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1002\/jcp.29328","article-title":"Haspin inhibition delays cell cycle progression through interphase in cancer cells","volume":"235","author":"Wang","year":"2020","journal-title":"J. Cell Physiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s12276-021-00635-6","article-title":"Aurora kinase A, a synthetic lethal target for precision cancer medicine","volume":"53","author":"Mou","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1158\/1078-0432.CCR-18-0440","article-title":"Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck","volume":"25","author":"Lee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/2159-8290.CD-18-0469","article-title":"Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene","volume":"9","author":"Gong","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1038\/s41467-018-05694-4","article-title":"Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells","volume":"9","author":"Wu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/15592294.2015.1028708","article-title":"VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage","volume":"10","author":"Salzano","year":"2015","journal-title":"Epigenetics"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/nar\/gkac198","article-title":"Multivalent DNA and nucleosome acidic patch interactions specify VRK1 mitotic localization and activity","volume":"50","author":"Budziszewski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molcel.2016.09.012","article-title":"Histone H2A T120 Phosphorylation Promotes Oncogenic Transformation via Upregulation of Cyclin D1","volume":"64","author":"Aihara","year":"2016","journal-title":"Mol. Cell"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00018-018-2811-2","article-title":"Implication of the VRK1 chromatin kinase in the signaling responses to DNA damage: A therapeutic target?","volume":"75","author":"Lazo","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Valbuena, A., Lopez-Sanchez, I., and Lazo, P.A. (2008). Human VRK1 is an early response gene and its loss causes a block in cell cycle progression. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0001642"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature12464","article-title":"RNAi screens in mice identify physiological regulators of oncogenic growth","volume":"501","author":"Beronja","year":"2013","journal-title":"Nature"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Colmenero-Repiso, A., G\u00f3mez-Mu\u00f1oz, M.A., Rodr\u00edguez-Prieto, I., Amador-\u00c1lvarez, A., Henrich, K.O., Pascual-Vaca, D., Okonechnikov, K., Rivas, E., Westermann, F., and Pardal, R. (2020). Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation. Cancers, 12.","DOI":"10.3390\/cancers12113465"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.4149\/neo_2021_210304N278","article-title":"VRK1 promotes proliferation, migration, and invasion of gastric carcinoma cells by activating \u03b2-catenin","volume":"68","author":"Wang","year":"2021","journal-title":"Neoplasma"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"20523","DOI":"10.1073\/pnas.0708800104","article-title":"A systematic interaction map of validated kinase inhibitors with Ser\/Thr kinases","volume":"104","author":"Fedorov","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0968-0004(02)02179-5","article-title":"Evolution of protein kinase signaling from yeast to man","volume":"27","author":"Manning","year":"2002","journal-title":"Trends Biochem. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1021\/acsmedchemlett.9b00082","article-title":"Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2","volume":"10","author":"Serafim","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"So, J., Mabe, N.W., Englinger, B., Moyer, S.M., Trissal, M.C., Marques, J.G., Kwon, J., Shim, B., Panditharatna, E., and Jeong, D. (2021). VRK1 is required in VRK2-methylated cancers of the nervous system. bioRxiv.","DOI":"10.1101\/2021.12.28.474386"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/j.1742-4658.2006.05256.x","article-title":"The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines","volume":"273","author":"Blanco","year":"2006","journal-title":"FEBS J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"23757","DOI":"10.1074\/jbc.M112.353102","article-title":"Vaccinia-related Kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage","volume":"287","author":"Monsalve","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbamcr.2016.02.005","article-title":"VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage","volume":"1863","author":"Monsalve","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2021.09.008","article-title":"Targeting the ATM Kinase to Enhance the Efficacy of Radiotherapy and Outcomes for Cancer Patients","volume":"32","author":"Kirsch","year":"2022","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"107450","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1158\/1535-7163.MCT-21-0305","article-title":"ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non-Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts","volume":"20","author":"Baschnagel","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"111692","DOI":"10.1016\/j.mrfmmm.2020.111692","article-title":"Targeting DNA-PK in cancer","volume":"821","author":"Damia","year":"2020","journal-title":"Mutat. Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2020.12.015","article-title":"Structure of an activated DNA-PK and its implications for NHEJ","volume":"81","author":"Chen","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/0008-5472.CAN-21-1756","article-title":"DNA-PKcs: A Targetable Protumorigenic Protein Kinase","volume":"82","author":"Dylgjeri","year":"2022","journal-title":"Cancer Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"abc7275","DOI":"10.1126\/scitranslmed.abc7275","article-title":"Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice","volume":"13","author":"Fang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and as Orthotopic Xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/4050\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:13:27Z","timestamp":1760141607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/16\/4050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":178,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14164050"],"URL":"https:\/\/doi.org\/10.3390\/cancers14164050","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}